KIORA PHARMACEUTICALS, INC. Increase (Decrease) in Lease Acquisition Costs
KIORA PHARMACEUTICALS, INC. (KPRX) had Increase (Decrease) in Lease Acquisition Costs of AUD 25.00 thousand as of 2022-05-13, per its 10-Q filed 2022-07-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInLeaseAcquisitionCosts · last filed 2022-07-08
- 2022-05-13: Increase (Decrease) in Lease Acquisition Costs 25.00K AUD.
AUD
| Period end | Increase (Decrease) in Lease Acquisition Costs |
|---|---|
| 2022-05-13 | 25.00K AUD 10-Q · filed 2022-07-08 |
USD
| Period end | Increase (Decrease) in Lease Acquisition Costs |
|---|---|
| 2022-02-01 | $38.70K 10-Q · filed 2022-07-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |